CompletedPhase 2NCT01078662
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
Studying Body integrity dysphoria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AstraZeneca
- Principal Investigator
- Jane Robertson, BSc, MBCHB, MDAstraZeneca
- Intervention
- olaparib(drug)
- Enrollment
- 298 target
- Eligibility
- 18-130 years · All sexes
- Timeline
- 2010 – 2024
Study locations (12)
- Research Site, West Hollywood, California, United States
- Research Site, Philadelphia, Pennsylvania, United States
- Research Site, Melbourne, Australia
- Research Site, Randwick, Australia
- Research Site, Cologne, Germany
- Research Site, Haifa, Israel
- Research Site, Jerusalem, Israel
- Research Site, Petah Tikva, Israel
- Research Site, Ramat Gan, Israel
- Research Site, Tel Aviv, Israel
- Research Site, Madrid, Spain
- Research Site, Lund, Sweden
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01078662 on ClinicalTrials.govOther trials for Body integrity dysphoria
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06898905Hyperfractionated Dual Equivalent Fractionated Radiation TherapyYale University
- RECRUITINGPHASE1NCT06966388Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing RadiationVirginia Commonwealth University
- RECRUITINGPHASE1, PHASE2NCT06853015Double Dose 4-AP on Functional Recovery After Spinal Cord InjuryShirley Ryan AbilityLab
- ACTIVE NOT RECRUITINGPHASE3NCT05456425A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With PterygiumCloudbreak Therapeutics, LLC